Alabama Medical Cannabis Director to Retire in October

John McMillan will step down from his role at the Alabama Medical Cannabis Commission on October 29, 2026.

Updated on Oct. 19, 2026 in People

Alabama Medical Cannabis Director to Retire in October

Live Poll

Do you trust your local government agencies to resolve complex licensing delays efficiently?

Alabama Medical Cannabis Commission director John McMillan announced his upcoming retirement effective October 29, 2026. He has served as the agency's first and only leader since its inception five years ago.

Why it matters

McMillan's departure marks a significant leadership transition for the state agency following a tenure defined by legal challenges and regulatory delays in the permitting process. His exit signals a new phase for Alabama's developing medical marijuana industry.

John McMillan served as the director of the Alabama Medical Cannabis Commission for a 5-year tenure. The commission's history is marked by a yearslong delay and multiple lawsuits regarding the state permitting process.

The players

John McMillan

He is the first and only director of the Alabama Medical Cannabis Commission and served in the role for five years.

Alabama Medical Cannabis Commission

This state entity, which operates out of Montgomery, is responsible for regulating the production and distribution of medical cannabis within Alabama.

The details

The commission is moving to appoint a transition committee to manage a nationwide search for a successor. Board members have stated that they will also consider internal candidates for the leadership role as they prepare for the post-McMillan era.

October 29, 2026: John McMillan retires from the commission.

Market Landscape

This leadership transition follows the regulatory framework established by the Alabama Medical Cannabis Commission Act. The shift impacts how the agency navigates the competitive and legal pressures surrounding state medical cannabis rollout.

Residents should anticipate potential shifts in commission policy or operational speed as the board conducts its search for new leadership. This change may influence the timeline for pending permit approvals and the state's medical cannabis market rollout.

The takeaway

McMillan's exit concludes an initial five-year chapter characterized by complex legal and regulatory hurdles for the agency. Prospective stakeholders should monitor commission meetings for updates on the transition committee and the selection of the next director.